Campus Alert: Find the latest UMMS campus news and resources at umassmed.edu/coronavirus

Page Menu

Robert W Finberg

UMassMed Faculty Page

Inventions:

Title: Incorporation/Packaging Viral/Tumor Antigens in Virus-like Particle. UMMS15-47; Patent Pending.

  • The invention relates to a vaccine for Eptein Barr Virus. The prophylactic is a recombinant virus-like particle (VLP) comprising a Newcastle disease virus (NDV) matrix (M) protein, a NDV nucleocapsid (NP) protein, and one or more tumor-associated EBV antigens that is capable of illiciting CD4+ and CD8+ T cell responses.

Title: MULTIVALENT LIPOSOME FORMULATIONS. UMMS13-28; Patent 9,408,890.  

  • The present technology relates to the treatment or prevention of infection, by administration of a liposome composition linked to binding targets. The compositions typically bind the virus (or virions), e.g., influenza, or bacteria, e.g., Streptococcus pneumonia, with high affinity to reduce or prevent infectivity. The technology is used to reduce or prevent the effects of a toxin, e.g., ricin, with high affinity to reduce or prevent toxin entry into a cell. Further, this invention discloses sulfated polysaccharides and sulfated polysaccharide compositions, which can prevent or treat viral infection, specifically respiratory syncytial virus (RSV).

Title: An IFN╬▓ Reporter Cell Line, clone SZ34. UMMS12-01; Patent Pending. 

  • Large-scale and high throughput screen for compounds that module type I interferons identify potential therapeutics that block viral replication. Clone SZ34 is a stabilly transfected human embryonic kidney cell (HEK) with expression plasmids for an IFN-Beta-promoter-driven firefly luciferase reporter gene (IFN-Beta-Luc).

Title: COMPOUNDS FOR MODULATING TLR2. UMMS09-52 Patent 8,609,6639,271,972

  • Viral infection causes damage to the host via stimulation of production of host cytokines. These processes can culminate in edema and damage to host organs. From screening, this novel invention identifies molecules that could potentially inhibit the cytokine response to viral infection by inhibiting RNA virus-mediated TNF-alpha production. The current invention discloses methods of the system used to screen, a TLR2 and CD14 stable cell line, and molecular inhibitors of Lymphocytic Choriomeningitis Virus (LCMV) induced cytokine production. These newly discovered molecules may facilitate amelioration of symptoms in a broad range of hemorrhagic fever viruses.

 

Innovation TopicsBiologicsInfectious DiseaseVaccinesEpstein barr virus, InfluenzaPneumoniaRespiratory syncytial virus, Research Tools, AntiviralCell line Small MoleculesHigh throughput screeningVirologyInfectious DiseaseImmunologyImmune edemaHemorrhagic feverLymphocytic Choriomeningitis Virus (LCMV)